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Transition of a clinical practice to use of subdural 
drains after burr-hole evacuation of chronic 
subdural haematomas: The Helsinki experience 
Abstract  
Background A number of randomised controlled trials have shown the benefit of drain in 
operative treatment of chronic subdural haematomas (CSDHs). However, few reports 
describe real life result when adopting the drain placement into clinical practice. We report 
the results following a change in practice at Helsinki University Hospital from no drain to 
subdural drain (SD) placement after burr-hole craniostomies for CSDHs. 
 
Methods We conducted a retrospective observational study including consecutive patients 
undergoing burr-hole craniostomies for CSDHs. We compared outcomes between a six-
month time period when the SD placement was arbitrary (July to December 2015) and a time 
period when SD placement for 48 h was routine (July to December 2017). Our primary 
outcome of interest was recurrences requiring reoperation within six months. Furthermore, 
patient outcome, infections and other complications were assessed. 
 
Results A total of 161 patients were included, of which 71 (44%) were in the SD group and 
90 (56%) in the non-drain group. There were no differences in age, comorbidities, history of 
trauma or use of antithrombotic medication between the groups (p>0.05). Recurrences within 
six months occurred in 18% of patients in the non-drain group compared to 6% in the SD 
group (p=0.028; OR 0.28; 95% CI 0.09-0.87). There were no differences in neurological 
outcome (p=0.72), mortality rate (p=0.55), infection rate (p=0.96) or other complications 
(p=0.20). 
 
Conclusions The change in practice from no drain to SD after burr-hole craniostomies for 
CSDHs effectively reduced the six-month recurrence rate without any effect on patient 
outcome, infections or other complications. 
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Introduction 
The incidence of chronic subdural haematomas (CSDHs) ranges from 1.7 to 18 per 100,000 
people. In patients older than 65 years, this rate increases to 58 per 100,000 people, making 
CSDHs one of the most common neurosurgical conditions.1,2 Most physicians would agree 
that nonsurgical treatment is recommendable with asymptomatic patients who have small 
CSDHs.3 For symptomatic CSDHs, burr-hole evacuation has become the most preferred 
treatment method,4,5 as it results in rapid resolution of the symptoms and a short period of 
hospitalisation. Other surgical options, such as using two burr-holes, twist drill craniostomy 
or even craniotomy in selected patient population have been used to treat CSDHs.2,3 
 
Up to date, there is a lack of consensus regarding the most optimal surgical technique.6 Even 
among Scandinavian centres, surgical techniques differ.7 The recurrence rates vary from 3% 
to 33% and may depend on both treatment- and patient-related factors.8–11 Many studies 
indicate that the recurrence rate is most effectively reduced by placing either a subdural or 
subgaleal drain.12–16 In a randomised controlled trial (RCT) by Santarius et al.,16 the 
placement of a subdural drain (SD) after burr-hole evacuation reduced the rate of recurrence 
from 24% to 9%. 
 
Although the use of a drain has been reported to reduce recurrence rates, some studies still 
dispute this.11,17 However, numerous questionnaire surveys indicate that there is an evidence-
practice gap in the usage of drains, as not all neurosurgeons place them regularly.4,18–22 
Despite reported evidence supporting the benefits of drain placement, drain usage in 
everyday practice within the neurosurgical department of Helsinki University Hospital was 
arbitrary until, on April 1, 2017, consistent management of CSDHs with subdural drains was 
established in our clinic.  
 
Due to the stricter inclusion and exclusion criteria of RCTs, the benefits of drain usage as 
shown by such trials may not necessarily reflect the real clinical setting.23 Still, there is a need 
for real-life observational studies to confirm results from RCTs.24 Thus, our aim was to assess 
whether the change of clinical practice to start using subdural drains had translated into a 
lower recurrence rate. Specifically, our primary goal was to confirm if patients treated with 
postoperative drains experienced lower recurrence rates compared to patients not receiving 
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drains. The secondary aim was to compare the changes in haematoma size, complications and 
patient outcome. 
Material and methods 
Ethical considerations 
The ethics committee of Helsinki University Hospital approved the study and waived the 
need for informed consent (HUS 1799/2018). 
Study setting and data collection 
On April 1, 2017, the use of subdural drain after burr-hole craniostomy for CSDH evacuation 
became routine at our clinic. Thus, to assess the effect of subdural drain usage on six-month 
recurrence risk, we chose time periods to represent the pre-drain era (July to December 2015) 
and the drain era (July to December 2017). During these time periods, we assessed all 
patients who underwent operations for CSDHs at the Department of Neurosurgery at Helsinki 
University Hospital. The non-drain group included patients from the pre-drain era and from 
this group, we excluded all patients that were treated with a drain. The subdural drain group 
included patients from the drain era and from this group, we excluded those not treated with a 
subdural drain and those treated with another type of drain than a subdural drain. We 
excluded patients who had undergone previous intracranial operations for any reason, as well 
as those with shunts for cerebrospinal fluid diversion or subdural haematomas treated with 
other methods (subgaleal drain or IRRAflow catheter). (Figure 1) 
 
All data concerning patients’ medical history, imaging and treatment is stored in Helsinki 
University Hospital’s electronic health records (EHRs). We retrospectively reviewed and 
analysed patients’ EHRs and their pre- and postoperative head computerised tomography 
(CT) scans or brain magnetic resonance images (MRIs). From EHRs, we obtained patients’ 
baseline and follow-up data concerning mobility and morbidity, history of head trauma 
during the preceding 12 months, most prominent symptom causing disability to the patient, 
modified Rankin scale (mRS) scores,25 medical history and existence of limb weakness or 
dysphasia. To ensure coherency, a single investigator assessed all clinical data. 
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Two senior neurosurgeons analysed all the imaging data from CT and MRI scans. We 
defined the subdural collection as predominantly hypodense, isodense or mixed by comparing 
the density of the collection to the adjacent brain.26 We also measured the maximum 
transition of the anatomical midline structures from the midline and determined the midline 
shift. On bilaterally operated haematomas, we recorded which side caused the midline shift. 
Further, we measured the width, length and height of the collection and, using formula 
ABC/2,27 assessed the volume of the haematoma. The CSDH volume reduction was analysed 
by comparing pre- and postoperative CT or MRI images. We also recorded the extent of basal 
cistern effacement, patency of cortical sulci and presence of contusions.  
Burr-hole craniostomy procedure 
As a routine, all burr-hole craniostomies at Helsinki University Hospital are performed under 
local anaesthesia, often combined with intravenous sedation with benzodiazepines and/or 
opioids during the operation. Here, general anaesthesia is used only if the neurosurgeon or the 
anaesthesiologist considers it unsafe to perform the procedure under local anaesthesia 
(applicable to only one patient in the current cohort). Typically, the surgeon drills one 14-mm 
burr-hole over the maximum convexity of the haematoma. In the case of an expansive 
bilateral haematoma, the surgeon operates on both sides. After opening the dura, the surgeon 
washes the subdural collection with warm (body temperature) Ringer’s lactate saline until 
rinsing appears clear. The operating surgeon decides whether or not to insert a subdural drain. 
The subdural drain used in this study was Spiegelberg Ventricular Catheter 10F (NeoNordic, 
Odense, Denmark), made of radiopaque polyurethane (length 270 mm, inner diameter 1.9 
mm and outer diameter 3.3 mm). The surgeon tunnels the drain under subgaleal skin 
approximately 5 cm from the incision, and it is linked to a ventricular drainage bag with a 
connector. The drainage bag is positioned at bed level and routinely removed after 48 h. We 
do not use postoperative prophylactic antibiotics routinely. 
 
In 2015, drain usage was not mandatory in our clinic, and the use of subdural and subgaleal 
drains was sporadic. At the beginning of 2017, a new administrative guideline was enforced, 
and usage of subdural drains became a requirement except in cases where the surgeon 
believes drain usage would compromise the patient’s safety. Subdural drains are routinely left 
in place for 48 h. We allow patient mobilisation during drain treatment. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Tommiska 
 6 
Follow-up and outcome measures 
Approximately four to six weeks postoperatively, follow-ups were completed with all 
operated patients in the Helsinki Metropolitan Area at an outpatient clinic. For patients living 
outside of this area, a recommendation for follow-up was made to their local hospitals. For 
the follow-up, a routine head CT was recommended. If the residual haematoma or the 
patient’s symptoms required further assessment, the patient was invited monthly for further 
follow-ups until the collection or symptoms resolved. 
 
Our primary outcome was CSDH recurrence requiring reoperation within six months. Since 
no other institution performs intracranial operations in the catchment area of Helsinki 
University Hospital, all patients requiring reoperation are referred to this hospital. We 
consider reoperation in the case of a new CT scan–verified CSDH, with recurrent 
neurological symptoms or with a recurrent haematoma of similar or larger size compared to 
the primary CSDH. 
 
Our secondary outcomes included neurological outcome within seven days and at six months 
after the primary operation (measured by the mRS), 30-day and six-month mortality, length 
of stay in the neurosurgical ward, postoperative infections and other complications. A 
favourable postoperative neurological outcome was defined as mRS 0 to 3, and an 
unfavourable outcome as mRS 4 to 6. We also recorded all postoperative complications and 
determined whether they were related to the operation. Further, we obtained dates of deaths 
through the Finnish Population Registry (available to all Finnish citizens). 
Statistical analyses 
We compared categorical variables by using a chi-square test, adjusting the Bonferroni 
method when appropriate and using Fisher’s exact test when appropriate. We tested 
continuous variables for normality with the Shapiro-Wilk test and thereafter used the Mann-
Whitney U test to compare nonparametric data and a t-test to compare normally distributed 
data. Testing was also completed to find any differences in baseline characteristics between 
patients in the subdural drain and non-drain groups. To identify associations between 
variables and the risk of recurrence within six months, binary logistic regression analysis was 
employed, with adjustments made for differences in baseline characteristics between the 
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groups (reported as odds ratios [OR] and 95% confidence intervals [CI]). We used Kaplan-
Meier curves to show differences in time to recurrence within six months between patients 
treated with a subdural drain and those treated with no drain. We considered p-values under 
0.05 to be statistically significant.  We also performed a post-hoc logistic regression analysis 
assessing the association between drain and recurrence within six months, adjusting for age, 
sex, preoperative neurological deficit and use of antithrombotic medication. All analyses 
were done using SPSS 25.0 for macOS (IBM Corp, Armonk, NY, USA). 
Results 
Baseline characteristics  
We included a total of 161 patients in our study (Figure 1). There were no significant 
differences in baseline characteristics between patients treated with subdural drains and those 
treated with no drain (Table 1). Similarly, no substantial differences could be observed 
between patients treated in 2017 with subdural drains and those treated in 2017 without 
drains (Supplementary table 1). The only significant baseline finding was that patients in 
the subdural drain group had thicker haematomas (median 23 mm vs. 20 mm; p=0.007) 
(Table 2). 
 
The reasons for not inserting a subdural drain in 2017 were immediate brain expansion 
(N=11), membrane loculations (N=3), antithrombotic treatment (N=2), infection (N=1), head 
wound operation (N=1) and a surgeon’s statement that inserting a drain would be unsafe 
(N=1). 
 
The main presenting symptoms are shown in Figure 2. Altogether, 53% of patients had a 
motor deficit presented as gait disturbance or limb weakness.  
Recurrence rate of CSDHs 
The six-month recurrence rate of CSDHs was 6% (N=4/71) in the subdural drain group and 
18% (N=16/90) in the non-drain group (p=0.028). As there were no differences in patient 
baseline characteristics between the groups, we assessed the association between use of drain 
and risk of recurrence within six months using univariable logistic regression analyses. 
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Subdural drain usage was associated with an OR of 0.28 (95% CI 0.09-0.87) for recurrence 
within six months compared to no drain. Among unilateral CSDHs, the six-month recurrence 
rate was reduced from 17% (N=12/72) in the non-drain group to 5% (N=3/55) in the drain 
group (p=0.06). Among bilateral CSDHs, the six-month recurrence rates were 22% in the 
non-drain group (N=4/18) and 6% in the drain group (N=1/16) (p=0.22). All recurrences 
were treated by burr-hole craniostomy. (Table 3) 
 
The results of our analysis of factors possible associated with six-month recurrence of 
CSDHs are displayed in Table 4. Apart from subdural drain usage, there were no other risk 
factors significantly associated with recurrence. In the post-hoc logistic regression analysis, 
adjusting for age, sex, preoperative neurological deficit and use of antithrombotic medication, 
the use of subdural drain still independently associated with a reduced risk of six-month 
recurrence (OR 0.27; 95% CI 0.08-0.85; p=0.025).  
 
Prior to the diagnosis of a CSDH, 66% of patients (N=107/161) were on some type of 
antithrombotic medication. Preoperative use of antithrombotic medication did not associate 
with recurrent CSDHs. Postoperatively, antithrombotic medication was restarted prior to the 
first control (four to six weeks after operation) in 28% of patients (N=29/102), 17% (N=5) of 
which had a recurrent CSDH. Of the five patients, one was treated with a subdural drain and 
four were treated without one in the primary operation.  
 
Figure 3 shows a Kaplan-Meier curve of differences in time to six-month recurrence and risk 
of six-month recurrence between patients in each group. Notably, the risk of recurrence was 
highest in the first 30 days following the procedure, after which it remained low throughout 
the follow-up period.   
 
Secondary outcomes 
There were no significant differences between the groups regarding immediate postoperative 
mRS (p=0.85), six-month mRS (p=0.72), 30-day mortality (p=0.14), six-month mortality 
(p=0.55), hospital length of stay (p=0.17), need for further care (p=0.56), infections within 30 
days (p=0.85) or within six months (p=0.96) or other complications (p=0.20). (Table 3) Of 
all secondary outcomes, only volume reduction differed significantly between the subdural 
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and non-drain groups (mean volume reduction 70% vs. 50%; p=0.005). Postoperative 
infections and other complications are shown in detail in Supplementary table 2. All 
complications were diagnosed within seven days postoperatively. Noticeably, there were no 
wound infections, meningitides or intracranial empyemas. 
Discussion 
In our study, we showed that the transition to consistent use of subdural drains after burr-hole 
craniostomies for CSDHs in a real-life clinical setting (Helsinki University Hospital) reduced 
the six-month recurrence rate from 18% to 6% without any increase in infections or 
complications. Subdural drain usage did not affect patient outcome, but did correspond with a 
notable decrease in CSDH volume. Furthermore, we showed that CSDH recurrence often 
happens within the first 30 days after treatment, following which the risk of recurrence is 
low. Our findings are well in line with recurrence rate reductions reported in numerous 
RCTs.16,28–30   
 
Our findings indicating the predominance of aged patients and those with a recent history of 
head trauma (81%), as well as a sex ratio in favour of male (68%), are in line with previous 
reports.31–34 CSDHs are common in elderly patients and have a major impact on their 
independence. Many authors have reported a high rate of functional dependency, even in 
operated patients.31,33,35 In a report by Leroy et al., the age threshold of 75 years was 
associated with an unfavourable functional outcome.33 In our study, the patients’ median age 
was 78 years in the subdural drain group and 77 years in the non-drain group. Prior to 
diagnosis, 75% of our patients had been walking independently, and 70% of the drain group 
and 78% of the non-drain group were living independently. Six months after treatment, only 
80% had recovered to walk independently. In our study, we were unable to reproduce the 
reduction of mortality rate by drain usage reported by Santarius et al.16 Furthermore, in our 
study only 64% of patients recovered to good mRS, as compared to 84% reported by 
Santarius et al. These differences may be due to the fact that the patients in our study were 
slightly older than in the report by Santarius et al. therefore having more morbidity and a 
higher need for assistance. 
 
The use of antithrombotic medication is a pressing issue in patients with CSDHs. In recent 
meta-analysis,36 both anticoagulation and antiplatelet therapy had higher risks of recurrence. 
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In our study, two-thirds of patients were on some sort of antithrombotic medication. We did 
not find any association between preoperative use of antithrombotic medication and 
recurrence risk. Further, antithrombotic medication was restarted prior to the first follow-up 
(four to six weeks postoperatively) in 28% of the users, only 17% of which had a recurrent 
CSDH requiring reoperation. The number of recurrences in the antithrombotic users was too 
low to allow for any more detailed statistical analysis. Still, these low numbers suggest that 
excessive caution regarding restarting of antithrombotic medication after CSDH evacuation 
may not be as warranted as previously thought. However, more studies are needed on this 
topic.   
 
Our results were derived from retrospective analysis, which is prone to well-known 
limitations. Therefore, caution is advised in interpreting them. As mentioned, in the Helsinki 
catchment area, all patients in need of reoperation are sent to Helsinki University Hospital, 
since it is the only institution in the region that performs such operations. Therefore, we were 
able to obtain complete data in terms of six-month recurrence and mortality rates. 
Furthermore, six months of follow-up data was obtained for 79% of patients in terms of mRS, 
76% in terms of mobility and 75% in terms of infection rates. 
 
In the operative management of CSDHs, there are still numerous unsettled intra- and 
postoperative factors that contribute to the outcome. At Helsinki University Hospital, we 
routinely perform the procedures under local anaesthesia, while some institutions favour 
general anaesthesia.16 We typically use one burr-hole, while some centres prefer two.37 We 
use subdural drains rather than other drainage methods, i.e. active subdural drains, drains 
with continuous irrigation and drainage or subgaleal drains. No one method has been shown 
to be superior to another.7,9,15 We use intraoperative irrigation until fluid is clear. Some 
studies indicate that irrigation results in a better outcome,9 while others show that there is no 
disadvantage to placing a drain without irrigation.5,38,39 We keep the drain in place for 48 h, 
although elsewhere, the use of 12- to 18-h drainage has been reported.7 We allow patient 
mobilisation during drain treatment, while some opt for bed rest.11,40  
 
Although we observed a reduction in recurrences within six months after beginning to use 
subdural drains, it is important to note that there are several factors related to perioperative 
treatment that may affect the risk of recurrence. Evidence in favour of drain usage is ever 
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more convincing; however, there is still a need for further research in the field of treatment of 
CSDHs.  
 
Conclusions 
Subdural drain usage after burr-hole craniostomies for CSDHs has been shown to 
significantly reduce the risk of recurrence without affecting patient outcome, infections or 
complications. More research is required to identify other treatment-related factors that might 
further reduce this risk. 
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Figure captions 
 
Figure 1. Flow chart displaying the inclusion and exclusion criteria and the formation of 
study groups 
CSDH chronic subdural haematoma, SIH spontaneous intracranial hypotension 
 
Figure 2. Most prominent symptom causing disability to the patient 
 
Figure 3. Kaplan-Meier curve showing differences in time to six-month recurrence and risk 
of six-month recurrence between patients in the subdural drain and non-drain groups. Of 
patients in the non-drain group, 18% had a recurrence, most often occurring within the first 
30 days following treatment. Of patients in the subdural drain group, 6% had a recurrence.  
 
 
Legends for supplementary material 
 
Supplementary table 1  
Baseline characteristics drain vs. non-drain in 2017 
 
Supplementary table 2 
Postoperative infections and complications 
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Table 1 Baseline characteristics 
Variable All patients            N = 161 
Drain                    
N = 71 
Non-drain               
N = 90 p-value 
Age (years), median (range) 77 (46-95) 78 (57-93) 77 (46-95) 0.77 
Women 51 (32%) 21 (30%) 30 (33%) 0.61 
History of trauma 131 (81%) 62 (87%) 69 (77%) 0.08 
Pre-morbid mobility 0.40 
    Independent 119 (75%) 51 (74%) 68 (76%) 
    Stick 6 (4%) 3 (4%) 3 (3%) 
    Zimmer frame 24 (15%) 12 (17%) 12 (13%) 
    Wheelchair 5 (3%) 3 (4%) 2 (2%) 
    Bed-bound 4 (3%) 0 4 (4%) 
Pre-morbid residence 0.52 
    Independent 119 (74%) 50 (70%) 69 (78%) 
    Carer 23 (14%) 13 (18%) 10 (11%) 
    Residential 15 (9%) 6 (8%) 9 (10%) 
    Nursing 3 (2%) 2 (3%) 1 (1%) 
Medical history  
    Dementia 35 (22%) 16 (23%) 19 (21%) 0.83 
    Arrhythmia 57 (35%) 23 (32%) 34 (38%) 0.48 
    Cerebrovascular accident 40 (25%) 19 (27%) 21 (23%) 0.62 
    Hypertension 110 (68%) 45 (63%) 65 (72%) 0.23 
    Ischaemic heart disease 40 (25%) 18 (25%) 22 (24%) 0.89 
    DVT or PE* 3 (2%) 0 3 (3%) 0.26 
    COPD  7 (4%) 5 (7%) 2 (2%) 0.24 
    Diabetes  38 (24%) 16 (23%) 22 (24%) 0.78 
    Heart valve prosthesis 4 (2%) 1 (1%) 3 (3%) 0.63 
Antithrombotic drug history† 107 (66%) 48 (68%) 59 (66%) 0.78 
    Anticoagulant† 56 (35%) 26 (37%) 30 (33%) 0.66 
        Warfarin 35 (22%) 14 (20%) 21 (23%) 0.58 
        LMWH 12 (7%) 4 (6%) 8 (9%) 0.43 
        DOAC 12 (7%) 9 (13%) 3 (3%) 0.025 
    Antiplatelet† 58 (36%) 25 (35%) 33 (37%) 0.85 
        Acetylsalicylic acid, dipyridamole 52 (32%) 21 (30%) 31 (34%) 0.51 
        Clopidogrel, ticagrelor 12 (7%) 6 (8%) 6 (7%) 0.67 
Admission mRS score, median 3 (2-4) 3 (2-4) 3 (2-4) 0.61 
    0 2 (1%) 1 (1%) 1 (1%) 0.98 
    1 7 (4%) 3 (4%) 4 (4%) 
    2 39 (24%) 15 (21%) 24 (27%) 
    3 39 (24%) 18 (25%) 21 (23%) 
    4 47 (29%) 22 (31%) 25 (28%) 
    5 27 (17%) 12 (17%) 15 (17%) 
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Preoperative hemiparesis 78 (48%) 34 (48%) 44 (49%) 0.90 
Preoperative dysphasia 52 (33%) 26 (37%) 26 (29%) 0.32 
Categorical data as n (%) and continuous as median (IQR), unless otherwise stated. Data regarding mobility is 
missing for three patients and regarding residence and dysphasia missing for one patient. *Medication used within 12 
months. †Before detection of subdural haematoma.  
DVT deep venous thrombosis, PE pulmonary embolism, COPD chronic obstructive pulmonary disease, LMWH low-
molecular-weight heparin, DOAC direct oral anticoagulant, mRS modified Rankin scale 
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Table 2 Preoperative imaging characteristics 
Variable All patients N = 161 
Drain                   
N = 71 
Non-drain 
N = 90 p-value 
Side 0.39 
    Left 70 (44%) 34 (48%) 36 (40%) 
    Right 57 (35%) 21 (30%) 36 (40%) 
    Bilateral 34 (21%) 15 (22%) 18 (20%) 
Total haematoma volume, cm3 137 (93-175) 149 (99-170) 131 (92-178) 0.54 
Unilateral N = 127 N = 55 N = 72   
Haematoma density 0.90 
    Hypodense 32 (25%) 13 (24%) 19 (26%) 
    Isodense 10 (15%) 9 (16%) 10 (14%) 
    Mixed 43 (60%) 33 (60%) 43 (60%) 
Midline shift, mm 7 (4-10) 7 (3-10) 7 (4-10) 0.92 
Haematoma thickness, mm 22 (17-25) 23 (19-27) 20 (15-24) 0.007 
Haematoma volume, cm3 126 (88-155) 131 (86-157) 116 (88-151) 0.32 
Cortical sulci 0.07 
    Open 10 (8%) 3 (6%) 7 (10%) 
    Compressed 24 (19%) 6 (10%) 18 (25%) 
    Closed 93 (73%) 46 (84%) 47 (65%) 
Bilateral N = 34 N = 16* N = 18   
Midline shift, mm 2 (0-4) 0 (0-4) 3 (2-4) 0.08 
Side causing midline shift 0.13 
    Left 13 (38%) 4 (25%) 8 (45%) 
    Right 9 (27%) 3 (19%) 6 (33%) 
    No midline shift 12 (35%) 9 (56%) 4 (22%) 
Total haematoma volume, cm3 206 (159-254) 186 (151-241) 239 (184-261) 0.10 
Both sides separately N = 68 N = 27 N = 41 
Haematoma density 0.74 
    Hypodense 12 (18%) 5 (19%) 7 (17%) 
    Isodense 22 (32%) 10 (37%) 12 (29%) 
    Mixed 34 (50%) 12 (44%) 22 (54%) 
Haematoma thickness, mm 18 (15-21) 19 (16-22) 17 (14-21) 0.33 
Haematoma volume, cm3  108 (71-130) 100 (76-123) 108 (67-145) 0.74 
Cortical sulci 0.91 
    Open 6 (9%) 2 (7%) 4 (10%) 
    Compressed 21 (31%) 9 (33%) 12 (29%) 
    Closed 41 (60%) 16 (60%) 25 (61%)   
Data are n (%) or median (IQR). Neither basal cistern effacement nor contusion were observed in any of the patients. 
*Patients treated with subdural drain unilaterally or bilaterally. 
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Table 3 Univariable logistic regression analysis for primary and secondary outcomes in drain and non-drain 
groups 
Outcome Drain                 (N = 71) 
Non-drain              
(N = 90) OR (95% CI) p-value 
Recurrence within six months 
    All 4/71 (6%) 16/90 (18%) 0.28 (0.09-0.87) 0.028 
    Unilateral CSDHs 3/55 (5%) 12/72 (17%) 0.29 (0.08-1.08) 0.07 
    Bilateral CSDHs 1/16 (6%) 4/18 (22%) 0.23 (0.02-2.35) 0.22 
Postoperative mRS 0-3     
    At seven days 40/71 (56%) 52/90 (58%) 0.94 (0.50-1.77) 0.85 
    At six months 35/55 (64%) 48/72 (67%) 0.88 (0.42-1.83) 0.72 
Mortality 
    At 30 days 1/71 (1%) 6/90 (7%) 0.20 (0.02-1.70) 0.14 
    At six months 8/71 (11%) 13/90 (14%) 0.75 (0.29-1.93) 0.55 
Hospital stay in neurosurgical unit, days 3 (2-5) 2 (1-4) NA 0.17¶ 
Further care needed 45/71 (63%) 53/90 (59%) 1.21 (0.64-2.29) 0.56 
Postoperative complications* within seven days 8/71 (11%) 5/90 (6%) 2.16 (0.67-6.91) 0.20 
Postoperative infections† 
    Within 30 days 8/71 (11%) 11/90 (12%) 0.91 (0.35-2.40) 0.85 
    Within six months 16/56 (29%) 20/71 (28%) 1.02 (0.47-2.22) 0.96 
Worse mobility at six months‡ 10/48 (21%) 14/59 (24%) 0.85 (0.34-2.12) 0.72 
Haematoma volume reduction, cm3§ 103 (56) 72 (60) NA 0.005¶ 
Percentual volume reduction (%)§ 70 (31) 50 (39) NA 0.005¶ 
Data are n/N (%), median (IQR) or mean (SD). Odds ratios are calculated for binary outcomes using logistic 
regression. An odds ratio under one indicates that subdural drain is associated with a lower probability for the 
specific outcome and vice versa. *Postoperative complications included cerebral infarction, intracerebral 
haemorrhage, wound bleeding, epileptic seizure, unintended drain removal, cardiac failure, pulmonary embolism 
and epidural haematoma. †Postoperative infections included urinary tract infection, pneumonia, soft tissue 
infection, shingles, upper respiratory infection, erysipelas, gastroenteritis and non-specific infection. ‡Excluding 
patients dying before six months. §Missing for 44/161 (27%) patients. ¶Calculated using a non-parametric 
Mann-Whitney U test.  
OR odds ratio, CI confidence interval, CSDH chronic subdural haematoma, mRS modified Rankin scale, NA not 
applicable 
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Table 4 Factors associated with recurrence of chronic subdural haematomas requiring reoperation within six months 
Variable No recurrence      (N = 141) 
Recurrence         
(N = 20) OR (95% CI) p-value 
Age (years), median (range) 78 (46-95) 77 (56-90) 0.98 (0.94-1.02) 0.33 
Neurological deficit (hemiparesis or dysphasia) 60% 45% 0.54 (0.21-1.38) 0.20 
History of trauma 84% 65% 0.36 (0.13-1.01) 0.051 
Antithrombotic drug history* 65% 75% 1.60 (0.55-4.66) 0.39 
    Anticoagulant* 33% 50% 2.07 (0.80-5.31) 0.13 
    Antiplatelet* 38% 25% 0.55 (0.19-1.61) 0.28 
Preoperative mRS 0-3 53% 60% 1.32 (0.51-3.43) 0.57 
Preoperative mRS 4-5 47% 40% 0.76 (0.29-1.97) 0.57 
Unilateral haematoma  79% 75% 0.78 (0.26-2.31) 0.65 
Bilateral haematoma 21% 25% 1.29 (0.43-3.83) 0.65 
Midline shift, mm† 7 (3-10) 9 (4-11) 1.06 (0.95-1.19) 0.30 
Mixed-density clot 61% 42% 0.47 (0.18-1.25) 0.13 
Subdural drain 48% 20% 0.28 (0.09-0.87) 0.028 
Data are percentage of patients in the subgroup or median (IQR), unless otherwise stated. Odds ratios calculated using 
univariable logistic regression. An odds ratio over one indicates that the specific variable is associated with a higher 
probability for recurrence and vice versa. *Before detection of subdural haematoma. †Excluding bilateral haematomas.  
OR odds ratio, CI confidence interval, mRS modified Rankin scale 
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Supplementary table 1
Baseline characteristics drain vs. non-drain in 2017
Age (years), median (range) 78 (57-93) 78 (42-102) 0.67
Women 21/71 (30%) 9/26 (35%) 0.63
History of trauma 62/71 (87%) 18/26 (69%) 0.07
Pre-morbid mobility 0.58
    Independent 51/69 (74%) 17/26 (65%)
    Stick 3/69 (4%) 1/26 (4%)
    Zimmer frame 12/69 (17%) 5/26 (19%)
    Wheelchair 3/69 (4%) 3/26 (12%)
Pre-morbid residence 0.92
    Independent 50/71 (70%) 20/26 (77%)
    Carer 13/71 (18%) 5/26 (19%)
    Residential 6/71 (8%) 1/26 (4%)
    Nursing 2/71 (3%) 0/26
Medical history 
    Dementia 16/71 (23%) 2/26 (8%) 0.14
    Arrhythmia 23/71 (32%) 7/26 (27%) 0.61
    Cerebrovascular accident 19/71 (27%) 9/26 (35%) 0.45
    Hypertension 45/71 (63%) 18/26 (69%) 0.59
    Ischaemic heart disease 18/71 (25%) 7/26 (27%) 0.88
    DVT or PE* 0/71 1/26 (4%) 0.27
    COPD 5/71 (7%) 1/26 (4%) 0.99
    Diabetes 16/71 (23%) 8/26 (31%) 0.41
    Heart valve prosthesis 1/71 (1%) 1/26 (4%) 0.47
Antithrombotic drug history† 48/71 (68%) 15/26 (58%) 0.36
    Anticoagulant† 26/71 (37%) 7/26 (27%) 0.37
        Warfarin 14/71 (20%) 6/26 (23%) 0.72
        LMWH 4/71 (6%) 1/26 (4%) 0.99
        DOAC 9/71 (13%) 0/26 0.11
    Antiplatelet† 25/71 (35%) 9/26 (35%) 0.96
        Acetylsalicylic acid, dipyridamole 21/71 (30%) 9/26 (35%) 0.63
Variable p-valueDrain               N = 71
Non-drain         
N = 26
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        Clopidogrel, ticagrelor 6/71 (8%) 2/26 (8%) 0.99
Admission mRS score, median 3 (2-4) 4 (2-4) 0.99
        0 1/71 (1%) 0/26 0.94
        1 3/71 (4%) 2/26 (8%)
        2 15/71 (21%) 6/26 (23%)
        3 18/71 (25%) 5/26 (19%)
        4 22/71 (31%) 8/26 (31%)
        5 12/71 (17%) 5/26 (19%)
Preoperative hemiparesis 34/71 (48%) 5/25 (20%) 0.015
Preoperative dysphasia 26/71 (37%) 6/26 (23%) 0.21
Imaging characteristics
    Side 0.038
        Left 21/71 (30%) 15/26 (58%)         Midline shift, mm 0 (0-4) 3 (NA) 0.63
        Right 34/71 (48%) 8/26 (31%)         Side causing midline shift 0.54
        Bilateral 16/71 (23%) 3/26 (12%)             Left 4/16 (25%) 2/3 (67%)
    Total haematoma volume, cm3 149 (99-170) 84 (62-120) <0.001             Right 3/16 (19%) 0/3
    Basal cisterns open 71/71 (100%) 26/26 (100%) NA             No midline shift 9/16 (56%) 1/3 (33%)
        Total haematoma volume, cm3 186 (151-241) 178 (NA) 0.71
Unilateral N = 55 N = 23
        Haematoma density 0.09
    Both sides separately N = 27 N = 11
            Hypodense 13/55 (24%) 11/23 (48%)         Haematoma density 0.59
            Isodense 9/55 (16%) 1/23 (4%)             Hypodense 5/27 (19%) 3/11 (27%)
            Mixed 33/55 (60%) 11/23 (48%)             Isodense 10/27 (37%) 2/11 (18%)
        Midline shift, mm 7 (3-10) 5 (2-7) 0.11             Mixed 12/27 (44%) 6/11 (55%)
        Haematoma thickness, mm 23 (19-27) 15 (12-17) <0.001         Haematoma thickness, mm 19 (16-22) 15 (11-18) 0.049
        Haematoma volume, cm3 131 (86-157) 75 (62-116) <0.001         Haematoma volume, cm3 100 (76-123) 65 (51-84) 0.010
        Cortical sulci 0.038         Cortical sulci 0.41
            Open 3/55 (5%) 3/23 (13%)             Open 2/27 (7%) 1/11 (9%)
            Compressed 6/55 (11%) 7/23 (30%)             Compressed 9/27 (33%) 6/11 (55%)
            Closed 46/55 (84%) 13/23 (57%)             Closed 16/27 (59%) 4/11 (36%)
        Brain contusion 0/55 1/23 (4%) 0.29         Brain contusion 0/27 0/11 NA
Operation Operation
        Subdural fluid 0.59         Subdural fluid 0.002
            Clear 0/37 1/20 (5%)             Clear 0/21 1/6 (17%)
Bilateral p-valueDrain                  N = 16‡
Non-drain                 
N = 3
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            Straw 6/37 (16%) 5/20 (25%)             Straw 0/21 3/6 (50%)
            Engine oil 13/37 (35%) 7/20 (35%)             Engine oil 12/21 (57%) 2/6 (33%)
            Fresh blood 8/37 (22%) 4/20 (20%)             Fresh blood 2/21 (10%) 0/6
            Mixture 10/37 (27%) 3/20 (15%)             Mixture 7/21 (33%) 0/6
        Subdural fluid pressure 0.022         Subdural fluid pressure 0.90
            Low 6/53 (11%) 9/23 (39%)             Low 6/25 (24%) 3/11 (27%)
            Medium 31/53 (58%) 8/23 (35%)             Medium 12/25 (48%) 6/11 (55%)
            High 16/53 (30%) 6/23 (26%)             High 7/25 (28%) 2/11 (18%)
Article title: Transition of a clinical practice to use of subdural drains after burr-hole evacuation of chronic subdural haematomas: The Helsinki experience
Journal name: World Neurosurgery
Authors: Pihla Tommiska, Kimmo Lönnrot, Rahul Raj, Teemu Luostarinen, Riku Kivisaari
Corresponding author: Pihla Tommiska; Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; pihla.tommiska@helsinki.fi
Data are n/N (%) or median (IQR), unless otherwise stated. *Medication used within 12 months. †Before detection of subdural haematoma. ‡Patients treated with subdural drain 
unilaterally or bilaterally.
DVT  deep venous thrombosis, PE  pulmonary embolism, COPD  chronic obstructive pulmonary disease, LMWH  low-molecular-weight heparin, DOAC  direct oral anticoagulant, 
mRS  modified Rankin scale, NA  not applicable
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Postoperative infections and complications
Infections within one month
    Urinary tract infection 4 2 6
    Pneumonia 1 5 6
    Non-specific infection 1 2 3
    Pyelonephritis 1 1 2
    Shingles 1 1
    Soft tissue infection 1 1
  All 8 11 19
Infections within six months*
    Urinary tract infection 6 6 12
    Pneumonia 3 7 10
    Non-specific infection 2 4 6
    Upper respiratory infection 1 4 5
    Pyelonephritis 2 2 4
    Soft tissue infection 1 2 3
    Erysipelas 2 2
    Shingles 1 1
    Gastroenteritis 1 1
  All 18 26 44
Complications within seven days
    Cerebral infarction 2 2
    Wound bleeding 2 2
    Unintended drain removal 2 2
    Intracerebral haemorrhage 1 1 2
    Epileptic seizure 1 1 2
    Pulmonary embolism 1 1
    Epidural haematoma 1 1
    Cardiac failure 1 1
  All 8 5 13
*Missing for 34/161 (21%) patients.
Article title: Transition of a clinical practice to use of subdural drains after burr-hole evacuation of chronic subdural haematomas: The Helsinki experience
Journal name: World Neurosurgery
Authors: Pihla Tommiska, Kimmo Lönnrot, Rahul Raj, Teemu Luostarinen, Riku Kivisaari
Corresponding author: Pihla Tommiska; Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; pihla.tommiska@helsinki.fi
Drain        N 
= 71
Non-drain        
N = 90
All patients         
N = 161
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Tommiska 
 1 
Abbreviations and acronyms 
CI confidence interval  
COPD chronic obstructive pulmonary disease 
CSDH chronic subdural haematoma  
CT computerised tomography 
DOAC direct oral anticoagulant 
DVT deep venous thrombosis 
EHR electronic health record 
LMWH low-molecular-weight heparin 
MRI magnetic resonance imaging 
mRS modified Rankin scale 
OR odds ratio 
PE pulmonary embolism 
RCT randomised controlled trial 
SD subdural drain 
